Incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in North Carolina from December 2020 – February 2022

E Elyse M. Miller R Ross M. Boyce A Aaron M. Kipp L L Kristin Newby C Christopher W. Woods C Caitlin A. Cassidy A Annika K. Gunderson C C Suzanne Lea C Coralei E. Neighbors B Bonnie E. Shook-Sa R Richard Sloane A Anne P. Starling D David Wambui D Douglas Wixted A Aaron Fleischauer A Allison E. Aiello

Abstract

Background Surveillance estimates of SARS-CoV-2 infections over time have relied on mandatory clinician and laboratory reporting. These estimates increasingly underestimated true viral incidence due to asymptomatic infections, variable access to testing, and self-administered diagnostics. To overcome these limitations, the North Carolina Department of Health and Human Services partnered with academic researchers to conduct three concurrent population-based longitudinal cohort studies in three distinct North Carolina counties to offer more accurate estimates of the incidence, prevalence, and vaccination rates for SARS-CoV-2. Methods We enrolled and followed adult residents of three North Carolina counties from August 2020-February 2022. Demographic and health information was collected in biweekly surveys. Nasal swabs were collected biweekly and tested for SARS-CoV-2 using PCR testing. Blood samples were collected monthly and tested for antibodies to the SARS-CoV-2 nucleocapsid and spike proteins. We calculated monthly seroprevalence, sero-incidence, PCR test positivity, and vaccination uptake. Results We enrolled 646 participants. Routine blood samples and nasal swab samples were contributed by 639 and 642 participants, respectively. By February 2022, 98% (95% CI: 97.4–98.2) had antibodies to the SARS-CoV-2 spike protein, and 13% (95% CI: 12.4–14.2) had antibodies to the nucleocapsid protein, indicating viral exposure. PCR testing detected infection among 14% (95% CI: 13.1–15.0) of participants, but cumulative PCR test positivity was only 1.3% (95% CI: 1.2–1.4). Over half of PCR-detected infections were asymptomatic. By February 2022, 97% of participants had completed the primary vaccine series, and 52% had received a booster dose. Conclusions Nearly all participants had anti-SARS-CoV-2 antibodies by the end of follow-up, primarily through vaccination. The incidence of PCR-detected infections was similar to antibody testing, but PCR test positivity substantially underestimated incident infections. These findings emphasize the importance of prospective infection monitoring via antibody testing in a comprehensive approach to tracking viral infections in the community setting.

Article Details

Journal PLoS ONE
Volume / Issue Vol. 20, Issue 10
Published October 08, 2025
Pages e0332645
ISSN 1932-6203
Publisher Public Library of Science

Journal Info

PLoS ONE

Public Library of Science

ISSN: 1932-6203 Open Access Health Sciences

Authors (16)

E

Elyse M. Miller

R

Ross M. Boyce

A

Aaron M. Kipp

L

L Kristin Newby

C

Christopher W. Woods

C

Caitlin A. Cassidy

A

Annika K. Gunderson

C

C Suzanne Lea

C

Coralei E. Neighbors

B

Bonnie E. Shook-Sa

R

Richard Sloane

A

Anne P. Starling

D

David Wambui

D

Douglas Wixted

A

Aaron Fleischauer

A

Allison E. Aiello